Popular terms

[SEARCH]

Codon topics
Hydrocodone
Nucleic Acid
Acetaminophen
Carboxylic Acid
Benzoic Acid
Genetically
Recombinant
Amino Acid
Nucleotide
Reverse Transcriptase Inhibitors
Reverse Transcriptase Inhibitor
Reverse Transcriptase
Antibodies
Base Sequence
Replication

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Codon patents



      
           
This page is updated frequently with new Codon-related patent applications. Subscribe to the Codon RSS feed to automatically get the update: related Codon RSS feeds. RSS updates for this page: Codon RSS RSS



Date/App# patent app List of recent Codon-related patents
07/16/15
20150197544 
 Compositions comprising enzyme-cleavable oxycodone prodrug patent thumbnailCompositions comprising enzyme-cleavable oxycodone prodrug
The embodiments provide compound kc-8, n-1-[3-(oxycodone-6-enol-carbonyl-methyl-amino)-2,2-dimethyl-propylamine]-arginine-glycine-malonic acid, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug, compound kc-8, that provides controlled release of oxycodone.
Signature Therapeutics, Inc.


07/16/15
20150196611 
 Pharmaceutical composition and methods for modulating immune system, preventing, pretreating and/or treating cancers patent thumbnailPharmaceutical composition and methods for modulating immune system, preventing, pretreating and/or treating cancers
This invention provides a pharmaceutical composition for modulating immune system comprising at least one polysaccharide extracted from radix astragali, radix codonopsis, ganoderma sinense, or mixtures thereof, and their extraction process. The present invention further relates to a method of modulating immune system by applying said pharmaceutical composition to a subject suffering from cancers, and a method of preventing and/or pretreating and/or treating cancers in the subject, where said method comprises applying said pharmaceutical composition before/during chemotherapy..
Hong Kong Baptist University


07/09/15
20150191721 
 Expression of maize codon optimized proteins in pseudomonas fluorescens patent thumbnailExpression of maize codon optimized proteins in pseudomonas fluorescens
Compositions and methods for improving expression of a recombinant protein or polypeptide of interest in a host cell are provided. Compositions comprising a polynucleotide coding sequence for a btbooster are provided using a plant optimized system.
Dow Agrosciences Llc


07/09/15
20150190451 
 Herbal composition and a  the treatment of hyperlipidemia caused by excessive consumption of lamb patent thumbnailHerbal composition and a the treatment of hyperlipidemia caused by excessive consumption of lamb
A composition and a method for treating hyperlipidemia caused by excessive consumption of lamb. The composition comprises in various parts: root of anhwei barberry, folium isatidis, garden erphorbia herb, aster ageratoides, vietnamese sophora root, codonopsis ianceolata, all-grass of snakefoot clubmoss, apanese stephania root, amur barberry root, thymifoious euphorbia herb, puff-ball, meadowrue root and rhizome, cottonrose hibiscus flower, common lantana leaf, herba orostachyos, japanese dock root, pubescent holly root, chinese brake herb, fruit of tree-of-heaven ailanthus, chinese iris seed, european verbena herb, datura seed, wild buckwheat rhizome, filliform cassytha herb, fig, radix cynanchi atrati, bittersweet herb, chinese pulsatilla root, spreading hedyotis herb, figwort root, herb of hygrometric boea, radix ardisiae crenatae, sowthistle tasselflower herb, weeping forsythia, roughhaired holly root, tree peony bark, membrane of chicken gizzard, carrot, medicated leaven, and radix glycyrrhizae.

07/09/15
20150190393 
 Use of oxycodone for treating visceral pain patent thumbnailUse of oxycodone for treating visceral pain
It is possible to effectively treat moderate to severe visceral pain by administering analgesic medications comprising the opioid oxycodone or pharmaceutically acceptable salts thereof. Visceral pain and especially acute (i.e.
Purdue Pharma L.p.


07/02/15
20150184250 
 Kras primers and probes patent thumbnailKras primers and probes
The present invention provides oligonucleotide primers or probes for the detection of a mutation of the kras gene. The invention also provides a method for detecting a mutation in the kras gene using the oligonucleotide primers or probes disclosed therein.
Response Genetics, Inc.


07/02/15
20150184150 
 Efficient, expansive, user-defined dna mutagenesis patent thumbnailEfficient, expansive, user-defined dna mutagenesis
The presently disclosed subject matter provides methods for the creation of one or more user-defined mutations that can be located anywhere in a target sequence, such as in a gene. These mutations can comprise single mutations, multiple mutations, or a comprehensive codon mutagenesis library, in which all possible single codon substitutions in a gene are created.
The Johns Hopkins University


07/02/15
20150182545 
 Materials and methods for treating diseases caused by genetic disorders using aminoglycosides and derivatives thereof which exhibit low nephrotoxicity patent thumbnailMaterials and methods for treating diseases caused by genetic disorders using aminoglycosides and derivatives thereof which exhibit low nephrotoxicity
Various aspects related to the preparation of congeners of the aminoglycosides gentamicin such as the congener c2 and using this compound or derivatives thereof and pharmaceutically active salts to treat diseases that involve genetic mutations which introduce a missense or premature stop codon into a gene. Still other aspects include treating human or animal patients with the gentamicin congener c2 and derivatives and pharmaceutical salt thereof to overcome, or to at least mitigate, the symptoms of disease and disorders such as some forms of becker's or duchenne muscular dystrophy, hurler's syndrome and cystic fibrosis that have as their etiology the presence of a premature stop codon in a gene whose proper expression is necessary for good health..
Indiana University Research And Technology Corp.


06/25/15
20150175672 
 Process for designing diverged, codon-optimized large repeated dna sequences patent thumbnailProcess for designing diverged, codon-optimized large repeated dna sequences
This disclosure concerns methods for the design of synthetic nucleic acid sequences that encode polypeptide amino acid repeat regions. This disclosure also concerns the use of such sequences to express a polypeptide of interest that comprises amino acid repeat regions, and organisms comprising such sequences..
Dow Agrosciences Llc


06/25/15
20150174121 
 Controlled release hydrocodone formulations patent thumbnailControlled release hydrocodone formulations
A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a c12/cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours..
Purdue Pharma L.p.


06/18/15
20150166557 

Preparation of 14-hydroxycodeinone sulfate


Synthetic methods are provided for preparation of oxycodone and salts thereof with an improved impurity profile. Thebaine is converted to 14-hydroxycodeinone sulfate intermediate to minimize a 7,8-dihydro-8,14-dihydroxycodeinone impurity.
Cody Laboratories, Inc.


06/18/15
20150166556 

Preparation of 14-hydroxycodeinone sulfate


Synthetic methods are provided for preparation of oxycodone and salts thereof with an improved impurity profile. Thebaine is converted to 14-hydroxycodeinone sulfate intermediate to minimize a 7,8-dihydro-8,14-dihydroxycodeinone impurity.
Cody Laboratories, Inc.


06/18/15
20150166555 

Preparation of 14-hydroxycodeinone sulfate


Synthetic methods are provided for preparation of oxycodone and salts thereof with an improved impurity profile. Thebaine is converted to 14-hydroxycodeinone sulfate intermediate to minimize a 7,8-dihydro-8,14-dihydroxycodeinone impurity.
Cody Laboratories, Inc.


06/18/15
20150166554 

Preparation of 14-hydroxycodeinone sulfate


Synthetic methods are provided for preparation of oxycodone and salts thereof with an improved impurity profile. Thebaine is converted to 14-hydroxycodeinone sulfate intermediate to minimize a 7,8-dihydro-8,14-dihydroxycodeinone impurity.
Cody Laboratories, Inc.


06/18/15
20150166553 

Synthesis of oxycodone hydrochloride


Synthetic methods are provided for preparation of oxycodone and salts thereof with an improved impurity profile. Thebaine is converted to 14-hydroxycodeinone sulfate intermediate to minimize a 7,8-dihydro-8,14-dihydroxycodeinone impurity.
Cody Laboratories, Inc.


06/18/15
20150166552 

Conversion of oxycodone base to oxycodone hydrochloride


Synthetic methods are provided for preparation of oxycodone and salts thereof with an improved impurity profile. Thebaine is converted to 14-hydroxycodeinone sulfate intermediate to minimize a 7,8-dihydro-8,14-dihydroxycodeinone impurity.
Cody Laboratories, Inc.


06/18/15
20150164808 

Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia


The present disclosure provides an extended release pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof..
Mallinckrodt Llc


06/04/15
20150152461 

Genetically encoded initiator for polymer growth from proteins


This invention pertains to methods for producing homogeneous recombinant proteins that contain polymer initiators at defined sites. The unnatural amino acid, 4-(2′-bromoisobutyramido)phenylalanine of formula 1, was designed and synthesized as a molecule comprising a functional group further comprising an initiator for an atom-transfer radical polymerization (‘atrp”) that additionally would provide a stable linkage between the protein and growing polymer.
Franklin And Marshall College


06/04/15
20150150928 

Composition for preventing and treating aids and preparation method thereof


The present invention relates to a pharmaceutical composition made from the following raw materials or from water and/or alcohol extracts of the following raw materials in parts by weight: 5 to 200 parts of ganoderma, 5 to 150 parts of radix panacis quinquefolii or radix et rhizoma ginseng, 1 to 90 parts of fermented cordyceps sinensis powder and/or 1 to 120 parts of cordyceps, and optionally one or more of 5 to 90 parts of flos rosae rugosae, 5 to 150 parts of ganoderma spore powder, 10 to 400 parts of radix pseudostellariae, 3 to 400 parts of radix codonopsis and 3 to 400 parts of radix astragali. Clinical trials demonstrate that the composition can significantly reduce hiv virus load in patients, increase the number of cd4+ cells, enhance the immunity of patients, has no considerable toxic and side effects, and is suitable for long-term use..
Jiangzhong Pharmaceutical Co., Ltd.


05/28/15
20150148537 

Process for reducing contaminating michael acceptor levels in oxycodone and other compositions


The present invention relates to processes for removal of michael acceptors from certain compositions wherein the composition is treated with a thiol-containing compound under conditions sufficient to remove michael acceptors and the resulting thiol-michael adducts. Certain embodiments of the present invention enable quantification and/or removal of michael acceptors and/or michael acceptor precursors..
Controlled Chemicals, Inc.


05/28/15
20150148525 

Methods of incorporating an amino acid comprising a bcn group into a polypeptide using an orthogonal codon encoding it and an orthorgonal pylrs synthase


The invention relates to a polypeptide comprising an amino acid having a bicyclo[6.1.0]non-4-yn-9-ylmethanol (bcn) group, particularly when said bcn group is present as: a residue of a lysine amino acid. The invention also relates to a method of producing a polypeptide comprising a bcn group, said method comprising genetically incorporating an amino acid comprising a bcn group into a polypeptide.
Medical Research Council


05/28/15
20150148367 

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


05/21/15
20150140639 

Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav


The present invention relates nucleic acid constructs for the production of recombinant parvoviral (e.g. Adeno-associated viral) vectors in insect cells, to insect cells comprising such constructs and to methods wherein the cells are used to produce recombinant parvoviral virions.
Uniqure Ip B.v.


05/21/15
20150140574 

Method for producing horseradish peroxidase recombinant protein using filamentous fungus


A modified polynucleotide has a different base sequence in at least one codon from a wild-type base sequence encoding a horseradish peroxidase polypeptide. The usage frequency of the modified codon of the polynucleotide corresponds to the codon usage frequencies of three filamentous fungal species in humicola, aspergillus, and trichoderma.
Meiji Seika Pharma Co., Ltd.


05/21/15
20150140139 

Composition for improving or promoting hair growth containing, as active ingredients, photosensitizer irradiated with light and peptide, and method using same


The present invention relates to a composition for improving or promoting hair growth, which contains, as an active ingredient, a photosensitizer-peptide conjugate, and to a method for screening for the hair growth promoter using the active ingredients. Ala, which is the photosensitizer of the present invention, is preferably activated by led radiation, and more preferably activated by radiation having a long wavelength of 650 to 675 nm.
Gwangju Institute Of Science And Technology


05/21/15
20150140103 

Vaccine


The present invention relates to a nucleic acid for vaccine that has undergone codon optimization for expression in bombyx mori, a vector comprising the nucleic acid, bombyx mori comprising the vector, and a method for producing a vaccine in which they are used.. .
The Institute Of Biological Resources


05/21/15
20150140095 

Once-a-day oxycodone formulations


The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean c24/cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.. .
Purdue Pharma L.p.


05/14/15
20150133665 

Processes and intermediates in the preparation of morphine analogs via n-demethylation of n-oxides using cyclodehydration reagents


A high-yielding method for the n-demethylation of oxycodone- and oxymorphone-n-oxides by the reaction of these compounds with cyclodehydration reagents has been performed. This method has been utilized to improve the synthesis of various morphine analogs, such as naltrexone, nalbuphone and naloxone..

05/14/15
20150132752 

Method for determining hla-a*24 group


The method of the present invention is a method for determining an hla-a*24 group, which includes determining the hla-a*24 group on the basis of the results of the typing of (a) a 211st base and (b) a 395th base, in which a (adenine) in the initiation codon for an hla gene is defined as the 1st base in the genomic dna of a test subject.. .

04/30/15
20150119556 

Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same


A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence.
Regeneron Pharmaceuticals, Inc.


04/30/15
20150119293 

Synthetic ligation reassembly in directed evolution


A directed evolution process for rapid and facilitated production from a progenitor polynucleotide template, of a library of mutagenized progeny polynucleotides wherein each of the 20 naturally encoded amino acids is encoded at each original codon position. This method, termed site-saturation mutagenesis, or simply saturation mutagenesis, is preferably based on the use of the degenerate n,n,g/t sequence.
Bp Corporation North America Inc.


04/23/15
20150110870 

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


04/16/15
20150105537 

Codon optimized sequence for an antiviral protein


A codon optimized nucleic acid sequence for interferon alpha-2a is provided which can be used for expression of interferon alpha-2a in e. Coli..
Biogenomics Limited


04/09/15
20150099798 

Variants of yeast ndi1 gene, and uses thereof in the treatment of disease associated with mitochondrial dysfunction


An isolated nucleic acid sequence encoding the yeast ndi1 protein of seq id no: 542 or a functional variant thereof is described. The nucleic acid sequence comprises at least 50 codons which are codon optimised compared with the sequence of yeast ndi1 gene of seq id no: 1..
Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin


04/09/15
20150099281 

Method for producing l-lysine using microorganisms having ability to produce l-lysine


The present invention relates to a modified polynucleotide encoding aspartate kinase (ec:2.7.2.4; hereinafter, referred to as lysc), transketolase (ec:2.2.1.1; hereinafter, referred to as tkt) or pyruvate carboxylase (ec:6.4.1.1; hereinafter, referred to as pyc), in which the initiation codon is substituted with atg, a vector including the same, a microorganism transformed with the vector, and a method for producing l-lysine using the same.. .
Cj Cheiljedang Corporation




Popular terms: [SEARCH]

Codon topics: Hydrocodone, Nucleic Acid, Acetaminophen, Carboxylic Acid, Benzoic Acid, Genetically, Recombinant, Amino Acid, Nucleotide, Reverse Transcriptase Inhibitors, Reverse Transcriptase Inhibitor, Reverse Transcriptase, Antibodies, Base Sequence, Replication

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Codon for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Codon with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.4365

3052

1 - 1 - 71